Edition:
United Kingdom

Biotest AG (BIOG_p.DE)

BIOG_p.DE on Xetra

26.40EUR
20 Apr 2018
Change (% chg)

€-0.20 (-0.75%)
Prev Close
€26.60
Open
€26.55
Day's High
€26.65
Day's Low
€26.30
Volume
16,875
Avg. Vol
33,125
52-wk High
€27.70
52-wk Low
€17.90

Select another date:

Tue, Feb 27 2018

BRIEF-Biotest FY Revenue Falls To EUR 378.1 Mln On Recall Of Human Albumin

* DGAP-ADHOC: BIOTEST AG: BIOTEST REACHES FY 2017 EBIT GUIDANCE

BRIEF-Biotest says Tiancheng to enter into domination agreement

* DGAP-ADHOC: BIOTEST AG: TIANCHENG INTENDS TO ENTER INTO A DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT WITH BIOTEST AG

BRIEF-Biotest: Creat Takeover Of Biotest Closed

* MAJORITY SHAREHOLDING (APPROX. 90% OF BIOTEST'S ORDINARY SHARES AND VOTING SHARE CAPITAL) OF CREAT IN BIOTEST Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

Biotest sheds U.S. business to allay U.S. concerns of Chinese takeover

FRANKFURT Biotest said on Friday that it has sold its U.S. operations, allaying national security concerns by U.S. authorities and paving the way for the German company's sale to a Chinese investor.

BRIEF-Biotest: All Conditions Met For Creat Takeover Of Biotest

* DGAP-ADHOC: BIOTEST AG: ALL CONDITIONS MET FOR CREAT TAKEOVER OF BIOTEST

BRIEF-Biotest: Trimodulin Concept For Phase III Study Coordinated With The Authorities

* DGAP-NEWS: BIOTEST AG: TRIMODULIN: CONCEPT FOR PHASE III STUDY SUCCESSFULLY COORDINATED WITH THE AUTHORITIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biotest 9-mth revenue at EUR 377.8 mln

* DGAP-NEWS: BIOTEST AG: BIOTEST GENERATES REVENUES OF EUR 377.8 MILLION IN THE FIRST NINE MONTHS 2017

UPDATE 1-Takeover of plasma firm Biotest by China's Creat hits wall in U.S.

* Biotest shares drop 12 percent to 7-month low (Adds share price, background)

China's Creat suffers setback in Biotest deal on U.S. scrutiny

FRANKFURT Chinese investor Creat Group Corp has withdrawn its application for U.S. approval of a planned 1.3-billion-euro ($1.51-billion) takeover of Biotest , the German blood plasma products maker said, sending its shares sharply lower.

Select another date: